51660-44-7

Usage

Uses

Used in Pharmaceutical Industry:
2-Propylpentanoic anhydride is utilized as an intermediate in the synthesis of various pharmaceuticals, contributing to the development of new medications and therapeutic agents. Its role in this industry is crucial for creating a wide range of drugs that address different health conditions.
Used in Organic Synthesis:
In the realm of organic synthesis, 2-Propylpentanoic anhydride is employed as a reagent, particularly for the formation of esters and amides. Its application in this field is vital for the production of various organic compounds that have diverse uses in different industries, including the chemical, agricultural, and manufacturing sectors.
Used as a Research Chemical:
2-Propylpentanoic anhydride is also used as a research chemical, enabling scientists and researchers to explore its properties and potential applications further. This can lead to the discovery of new uses and the development of innovative products and processes.

InChI:InChI=1/C16H30O3/c1-5-9-13(10-6-2)15(17)19-16(18)14(11-7-3)12-8-4/h13-14H,5-12H2,1-4H3

Upstream product

• 99-66-1 valproic acid 
• 2936-08-5 valproyl chloride 
• 108-24-7 acetic anhydride 

Downstream Products

• 18531-94-7 (R)-1,1'-Bi-2-naphthol 
• 18531-99-2 (S)-[1,1']-binaphthalenyl-2,2'-diol 
• 1260167-74-5 2-(4-(8-bromo-2-oxo-3-(2-propylpentanoyl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 

Relevant academic research and scientific papers

Synthesis and characterization of 6-O-acyl-2-O-α-D-glucopyranosyl-L- ascorbic acids with a branched-acyl chain

We previously reported the chemical synthesis of a series of novel monoacylated vitamin C derivatives, 6-O-acyl-2-O-α-D-glucopyranosyl-L- ascorbic acids (6-Acyl-AA-2G) possessing a straight-acyl chain of varying length from C4 to C18, as effective skin antioxidants. In this paper, we describe branched type of 6-Acyl-AA-2G derivatives (6-bAcyl-AA-2G) synthesized by use of a 2-branched-chain fatty acid anhydride as an acyl donor. The stability of 6-bAcyl-AA-2G in neutral solution was much higher than that of 6-Acyl-AA-2G, while they were susceptible to enzymatic hydrolysis for exerting vitamin C effect. These branched derivatives as well as 6-Acyl-AA-2G increased the radical scavenging activity against 1,1-diphenyl-2-picrylhydrazyl and the lipophilicity in octanol/water-partitioning systems with increasing length of their acyl group. In addition, the 6-bAcyl-AA-2G derivative with an acyl chain of C12, 6-bDode-AA-2G had the excellent solubility to various solvents, suggesting easy handling in cosmetic use. These characteristics of 6-bAcyl-AA-2G may be available for skin care application as an effective antioxidant.

Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands

We report new anticancer prodrugs, platinum(IV) derivatives of oxaliplatin conjugated with valproic acid (VPA), a well-known drug having histone deacetylase inhibitory activity. Like most platinum(IV) derivatives, the cytotoxicity of the conjugates was lower in cell culture than that of oxaliplatin, but greater than those of its Pt(IV) derivative containing biologically inactive axial ligands in several cancer cell lines. Notably, these conjugates display activity in both cisplatin sensitive- and resistant tumor cells capable of both markedly enhanced accumulation in tumor cells and acting in a dual threat manner, concurrently targeting histone deacetylase and genomic DNA. These results demonstrate the dual targeting strategy to be a valuable route to pursue in the design of platinum agents which may be more effective in cancer types that are typically resistant to therapy by conventional cisplatin. Moreover, platinum(IV) derivatives containing VPA axial ligands seem to be promising dual-targeting candidates for additional preclinical studies.

Ctc-[Pt(NH3)2(cinnamate)(valproate)Cl2] is a highly potent and low-toxic triple action anticancer prodrug

Pt(iv) prodrugs have gained tremendous attention due to their indisputable advantages compared to cisplatin. Herein, new Pt(iv) derivatives with cinnamic acid at the first axial position, and inhibitor of matrix metalloproteinases-2 and-9, histone deacetylase, cyclooxygenase or pyruvate dehydrogenase at the second axial position are constructed to develop multi-action prodrugs. We demonstrate that Pt(iv) prodrugs are reducible and have superior antiproliferative activity with IC50 values at submicromolar concentrations. Notably, Pt(iv) prodrugs exhibit highly potent anti-tumour activity in an in vivo breast cancer model. Our results support the view that a triple-action Pt(iv) prodrug acts via a synergistic mechanism, which involves the effects of CDDP and the effects of axial moieties, thus jointly leading to the death of tumour cells. These findings provide a practical strategy for the rational design of more effective Pt(iv) prodrugs to efficiently kill tumour cells by enhancing their cellular accumulation and tuning their canonical mechanism.

Isothiourea-Catalysed Regioselective Acylative Kinetic Resolution of Axially Chiral Biaryl Diols

An operationally simple isothiourea-catalysed acylative kinetic resolution of unprotected 1,1′-biaryl-2,2′-diol derivatives has been developed to allow access to axially chiral compounds in highly enantioenriched form (s values up to 190). Investigation of the reaction scope and limitations provided three key observations: i) the diol motif of the substrate was essential for good conversion and high s values; ii) the use of an α,α-disubstituted mixed anhydride (2,2-diphenylacetic pivalic anhydride) was critical to minimize diacylation and give high selectivity; iii) the presence of substituents in the 3,3′-positions of the diol hindered effective acylation. This final observation was exploited for the highly regioselective acylative kinetic resolution of unsymmetrical biaryl diol substrates bearing a single 3-substituent. Based on the key observations identified, acylation transition state models have been proposed to explain the atropselectivity of this kinetic resolution.

Valproic acid phospholipid derivative method for the preparation of (by machine translation)

The invention belongs to the field of the preparation of organic compounds, discloses valproic acid phospholipid derivative preparation method. The invention uses the tetrahydrofuran as the solvent, triethylamine does ties up acid agent, c b of the valproic acid in molar 10-50 °C lower reaction, filtration, distillation, and get c valeric anhydride, third fifth heavenly stem anhydride solution in adding haemolytical phosphatidyl choline, in 4-dimethylaminopyridine in under the catalysis of 60-85 °C reaction under 2-6 hours, adding acetone precipitate product, then using ethanol/acetone is refined to valproic acid phospholipid derivatives. This invention uses the valproic acid and anhydride reaction preparation third fifth heavenly stem pivaloyl, not the impact of the presence of acetic anhydride, of the easy purification third fifth heavenly stem anhydride to obtain high-purity, and then can be preparing high-purity of the phospholipid derivatives third propyl-acetic acid. (by machine translation)

Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands

We report new anticancer prodrugs, platinum(IV) derivatives of oxaliplatin conjugated with valproic acid (VPA), a well-known drug having histone deacetylase inhibitory activity. Like most platinum(IV) derivatives, the cytotoxicity of the conjugates was lower in cell culture than that of oxaliplatin, but greater than those of its Pt(IV) derivative containing biologically inactive axial ligands in several cancer cell lines. Notably, these conjugates display activity in both cisplatin sensitive- and resistant tumor cells capable of both markedly enhanced accumulation in tumor cells and acting in a dual threat manner, concurrently targeting histone deacetylase and genomic DNA. These results demonstrate the dual targeting strategy to be a valuable route to pursue in the design of platinum agents which may be more effective in cancer types that are typically resistant to therapy by conventional cisplatin. Moreover, platinum(IV) derivatives containing VPA axial ligands seem to be promising dual-targeting candidates for additional preclinical studies.

Ibuprofen acid anhydrides and prodrug pharmaceutical composition containing the same

Pharmaceutical compositions of the prodrug type, a process for the preparation thereof, a process for the preparation of the as prodrug functioning compounds and compounds obtained herein. The pharmaceutical compositions of the invention contain organic acid anhydrides with formula 1 through 5, as well as the pharmacological acceptable salts thereof as prodrug functioning compounds, together with a suitable pharmaceutically acceptable gaseous, liquid or solid carrier. The prodrug systems of the invention possess as favorable property that they amend the residence time of the pharmaceutical composition in the body by influencing the transport system. Furthermore they increase the biological availability because of the more lipophilic properties of the anhydride compared with the acid, so that this improved administration performance may contribute to lower dosages. Further the prodrug systems according to the invention contribute to the reduction of the complaints of patients, because the systems usually remove the unpleasant bitter taste and the flavor, whereas the gastro intestinal irritation of the organic acids is removed or reduced.